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treatment and caused by mutations in the dysferlin gene
(DYSF). One-third is missense mutations leading to dysferlin
aggregation and amyloid formation, in addition to defects
in sarcolemmal repair and progressive muscle wasting.
Dysferlin-null mouse models do not allow study of the
consequences of missense mutations. We generated a new
mouse model (MMex38) carrying a missense mutation in
exon 38 in analogy to a clinically relevant human DYSF variant
(DYSF p.Leu1341Pro). The targeted mutation induces all
characteristics of missense mutant dysferlinopathy, including
a progressive dystrophic pattern, amyloid formation, and
defects in membrane repair. We chose U7 small nuclear RNA
(snRNA)-based splice switching to demonstrate a possible
exon-skipping strategy in this new animal model. We show
that Dysf exons 37 and 38 can successfully be skipped in vivo.
Overall, the MMex38 mouse model provides an ideal tool
for preclinical development of treatment strategies for
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Dysferlin (DYSF, OMIM: 603009) is a 230 kDa large transmembrane
protein highly expressed in skeletal muscle.1 Dysferlin is found at the
sarcolemma and in subsarcolemmal vesicles. Dysferlin is important in
the wound healing of membranous microlesions in a calcium-depen-
dent manner.2–4 Mutations in the dysferlin gene (DYSF) cause limb
girdle muscular dystrophy 2B (LGMD2B)5 or the more distal forms,
Miyoshi myopathy6 and anterior tibial muscular dystrophy.7
Currently, dysferlinopathies cannot be treated. Over 500 different dis-
ease-causing mutations have been described (Leiden Open Variation
Database, last update March 31, 2017). One-third of those is missense
mutations. Some of them exhibit typical characteristics of a protein-
misfolding disease like protein aggregation, premature degradation,
and amyloid formation.8,9 We described a homozygous missense mu-
tation DYSF c.4022T > C (p.Leu1341Pro) in exon 38 in a family of
Arabic middle east origin with LGMD2B.9 The mutation affects
proper folding of the dysferlin C2E domain, and it leads to aggregate
formation of non-functional protein.198 Molecular Therapy: Nucleic Acids Vol. 13 December 2018 ª 2018
This is an open access article under the CC BY-NC-ND license (httpAll existing mouse models of dysferlinopathy, such as SJL/L, A/J,
BLA/J, or Dysf-knockout mice, lead to a complete absence of dysfer-
lin.2,10–14 Consequences of a single amino acid variation and of
protein misfolding could not be studied so far in an animal model.
Exon skipping is a therapeutic approach that uses short single-
stranded nucleic acid analogs to mask specific motifs in pre-mRNA
required for correct splicing. Antisense oligonucleotide (AON)-based
splice-switching approaches have been developed for therapeutic use
in human for Duchenne muscular dystrophy (DMD), spinal
muscular atrophy,15–20 and dysferlinopathy.21,22 However, splice-
modulating efficiency remains low in humans, and AONs must be
repeatedly applied throughout life using invasive injection protocols,
spurring research for more efficient and less invasive strategies. The
U7 small nuclear RNA (snRNA)-encoded antisense RNAs differ
from DNA-analog based AONs, in that they can easily be packaged
into a suitable viral vector (i.e., recombinant adeno-associated virus
[rAAV]) to transduce a wide variety of tissues, including skeletal mus-
cle. U7 snRNA belongs to the group of minor snRNAs that take part
in the processing of the 30 end of histone pre-mRNA.23 A native anti-
sense sequence embedded in the U7 small nuclear ribonucleoprotein
particle (snRNP) recognizes the 30 UTR of histone transcripts24,25 and
can be modified for therapeutic purposes.26–30 Therefore, AAV-U7
snRNA has several advantages over DNA analog chemistries, notably
as bearing high transduction efficiency associated with strong and
long-lasting antisense effect following a single systemic application.
Here we developed the first mouse model with a missense mutant
in Dysf. The mutation was first described in patients (DYSF
p.Leu1341Pro).9 We designed a U7-based exon-skipping strategy
and demonstrated the impact of exon removal on the dysferlinThe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characteristics of the New Animal Model Dysf-MMex38
(A) The index dysferlinopathy patient harbors the homozygous missense mutation DYSF c.4022T > C in exon 38. MMex38 mice carry the corresponding mutation Dysf
c.4079T > C leading toDysf p.Leu1360Pro (NCBI GenPept: NP_001071162.1, dysferlin isoform 2) (aDYSF p.Leu1341Pro, NM_003494) in the C2E domain (red asterisk) of
dysferlin protein. (B) On the protein level, the missense mutated dysferlin detected by Hamlet antibody is markedly reduced (western blot of quadriceps muscle of differently
aged mice; a-tubulin used as loading control). Dysf pLeu1360Pro does not localize at the membrane of MMex38 mice. Immunostaining of TA sections of MMex38 and WT
mousewith Hoechst and Romeo antibody. Scale bars, 20 mm. (C) Dystrophic changes worsen with age inMMex38mice (Gomori’s trichrome staining of MMex38 quadriceps
muscles). Scale bar, 50 mm. w, weeks of age. (D) Amyloid in MMex38 quadriceps muscle (Congo red staining). Scale bar, 50 mm. (E) Membrane repair after laser wounding is
impaired inMMex38 flexor digitorum brevis muscle fibers (number of fibers n = 20 from 3mice) compared toWT (number of fibers n = 24 from 4mice) in the presence of Ca2+.
Fluorescence intensity below wounding site, mean ± SEM; ****p < 0.0001, unpaired t test for the time points above 300 s.
www.moleculartherapy.orgmembrane repair activity. We prepared the molecular tools and viral
vectors to deliver the splice-switching constructs in vivo and in vitro.
We overcame the mutation by using AAV-U7 snRNA-mediated exon
skipping in a novel mouse model for dysferlinopathy. The feasibility
of the approach is demonstrated and technical limitations are
discussed.
RESULTS
MMex38 Mice Display the Human Phenotype of Missense
Mutant Dysferlinopathy
We generated a mouse model for missense mutant dysferlinopathy by
introducing the murine mutation Dysf c.4079T > C (NCBI Genbank:
NM_001077694.1) in exon 38 leading to p.Leu1360Pro (NCBI
GenPept: NP_001071162.1, dysferlin isoform 2) (Figure 1A; Fig-
ure S1). Mice carrying the homozygous missense mutation are calledMMex38 mice. The mutation is analogous to DYSF c.4022T > C
(p.Leu1341Pro) in exon 38 causing LGMD2B.9 The murine pheno-
type resembles the human disease progression and characteristics in
several aspects. Newborn mice clinically and histopathologically do
not display symptoms (data not shown). Signs of muscular dystrophy,
such as necrotic and regenerating muscle fibers, fiber splitting, and
fibrosis, first occurred in early adulthood (from week 12 onward)
(Figure 1C; quantification and statistics are demonstrated in Fig-
ure S2), and they progressed significantly with age. At 60 months of
age, more muscle fibers were replaced by fatty fibrosis (Figure 1C).
Wild-type littermates of any age never showed pathological alter-
ations in skeletal muscle.
On protein level Dysf p.Leu1360Pro led to a 90% reduction of
dysferlin as assessed by western blot. Immunofluorescence stain forMolecular Therapy: Nucleic Acids Vol. 13 December 2018 199
Figure 2. Functional Assessment of Exon 37- and 38-Truncated Dysferlin
(A) Schematic mapping of dysferlin domains on exons in pre-mRNA. (B) Dysferlin constructs introduced into dysferlin-null human myoblast via lentiviral transduction.
(C) Quantification of the fluorescent signal influx into woundedmyotubes over time. For each construct, the following number of myotubes was wounded: hDYSF_D37, n = 8;
hDYSF_D38, n = 15; hDYSF_D3738, n = 14; hDYSF_Full, n = 15; non-transduced, n = 14; and EGFP, n = 7. Data points represent means ±SEM; **p < 0.01 and ***p < 0.001,
unpaired t test for the time points above 350 s.
Molecular Therapy: Nucleic Acidsdysferlin on a frozen section revealed the absence of mutant dysferlin
at the sarcolemma but occasional accumulations (Figure 1B).9 As
described for the patients carrying DYSF missense mutations,8
MMex38 mouse muscle also displayed amyloid deposits at vessel
walls (Figure 1D) and at the sarcolemma at older age.
To assess dysferlin function inMMex38mouse muscle, we performed
the laser-wounding assay on isolated muscle fibers from MMex38
flexor digitorum brevis muscle ex vivo. Membrane repair was signif-
icantly delayed in MMex38 as compared to wild-type (WT) litter-
mates (Figure 1E), demonstrating that we had developed a fully
functional dysferlin-missense mutant mouse model suitable for
preclinical treatment attempts.
Dysferlin Devoid of Exons 37 and 38 Is Functional
We aimed to treat the Dysf c.4079T > C mutation by skipping the
entire exon 38. We first needed to establish whether dysferlin lacking
exon 38 would be functional. According to UniProt database annota-
tion, exon 38 and exon 39 encode dysferlin C2E domain (UniProt:
O75923) (Figure 2A).31 The length of the intron between exons 37
and 38 is only 118 nt, a distance that might be too short to interfere
efficiently with the splicing machinery by means of a splice-switching
strategy. We therefore also considered combined removal of exons 37
and 38. We cloned four human DYSF variants, and we expressed
them via lentiviral transduction in primary human myoblast cells
carrying a dysferlin null mutation (homozygous DYSF c.4872delG):
full DYSF (hDYSF_Full), DYSF without exon 37 (hDYSF_D37),
DYSF without exon 38 (hDYSF_D38), and DYSF without exons 37
and 38 (hDYSF_D3738) (Figure S3). All constructs were linked to
an EGFP reporter via P2A (Figure 2B) to enable sorting for trans-
duced cells (Figure S4A). Sorted myoblasts were differentiated into200 Molecular Therapy: Nucleic Acids Vol. 13 December 2018myotubes, and dysferlin expression was verified by immunostaining
of dysferlin-null myotubes (Figure S4B). The membrane-wounding
assay was used to demonstrate functional outcomes (Figure S5).2,3
Non-transduced DYSF-null myotubes and myotubes infected with
GFP only showed the highest fluorophore uptake, demonstrating
the expected delay in repairing minute sarcolemmal lesions in dysfer-
linopathy (Figure 2C). Myotubes transduced with full-length DYSF
normalized the membrane repair time (Figure 2C). hDYSF_D37
and hDYSF_D3738 demonstrated the same resealing performance
as hDYSF_Full. Transduction with hDYSF_D38 resulted in an only
incomplete membrane resealing, confirming our predicted caution
of deleting exon 38 only. Our data demonstrate that the partial dele-
tion of the C2E domain by simultaneous removal of both exons 37
and 38 restores dysferlin protein function in patient-derived dysfer-
lin-null cells. These results provide the rationale underlying a thera-
peutic strategy aimed at skipping mutated exons 37–38 in patients
experiencing dysferlinopathies with a missense mutation in exon 38.
U7 snRNA Antisense Sequences Skip Mouse Dysferlin Exons 37
and 38 in MDX Muscles In Vivo and in C2C12 Cells In Vitro
Pre-mRNA splicing is a highly complex machinery that involves
interaction between multiple RNA-binding proteins with a wide
spectrum of splicing silencers and enhancers.32 We used the relative
enhancer and silencer classification by unanimous enrichment
(RESCUE)-ESE algorithm to predict localization of potential exonic
splice enhancers (ESEs) in the mouse Dysf exon 37 and 38
sequence.33,34 We designed 12 antisense sequences spanning exon
38 and parts of neighboring introns of Dysf pre-mRNA (Figure 3A;
Table S1), based on their ability to mask exon 38 (U2.7, U4.7, U6.5,
U7.10, U8.2, U9.2, and U10.1), to target the intron 37–38 branching
(legend on next page)
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 13 December 2018 201
Figure 4. U7-Based Exon Skipping in MMex38 Mice
(A) Detection of exon skipping using RT-PCR and nested PCR for dysferlin mRNA spanning the region between exons 33 and 39. Densitometric quantification of exon
skipping in MMex38 mice using ImageJ is shown. (B) Sequencing of the skipped dysferlin. The presence of the junction between the exons 36 and 39 was verified.
(C) Detection of dysferlin expression in MMex38 TAs treated with U7 snRNAs using biotin-streptavidin western blot with Hamlet antibody (a-tubulin as loading control).
Densitometric quantification of dysferlin as a percentage of WT (C57BL6) using ImageJ is shown. (D) Immunostaining with Hoechst and Romeo antibody of TA sections of
MMex38 treated with U7 snRNAs and WT mouse treated with PBS. Scale bars, 20 mm.
Molecular Therapy: Nucleic Acidspoint (U1.7, U3.4, and U5.5), or to cover the acceptor splice site
of intron 37–38 (U2.7, U4.7, and U5.5). One sequence was designed
to target the donor site of intron 38–39 (U10.1). U11.1 and U12.2
masked both the acceptor site of intron 37–38 and the donor site of
intron 38–39. The sequence pairs U1.7/U3.4, U2.7/U4.7, and
U11.1/U12.2 masked the same regions of the mouse Dysf pre-
mRNA, but the rationale was to optimize the antisense sequences
to contain a nucleotide matching the so-called kiss domain.35 We
could not detect an advantage of this approach in our study. The
secondary structure of all U7 snRNAs was analyzed using RNAfold36
to exclude the existence of hairpin structures. The U7 snRNA con-
structs were packaged into rAAV2/9 viruses.
We first tested the suitability of our U7 snRNAs in 10-week-old MDX
mice. This mouse has been characterized extensively, and it has
been used for preclinical assessment of new treatment strategies. It
displays necrosis and regeneration of muscle fibers due to muscular
dystrophy. We injected each U7 construct into the anterior tibial
muscle of MDX mice. Three antisense sequences (U7.10, U8.2, and
U9.2) effectively induced exon skipping, as detected by RT-PCR
and nested PCR 4 weeks after delivery (Figures 3B and 3C). All ofFigure 3. Screening of U7 snRNA Antisense Sequences for Exon-Skipping Act
(A) Antisense sequences of U7 snRNA constructs mapped on the intron 37–38, exon 38,
of exon skipping using RT-PCR and nested PCR in MDXmice. The intermediate-sized b
(D) Densitometric quantification of exon skipping in MDX mice. (E) Sequencing of the ski
(F) Detection and densitometric quantification of exon skipping using RT-PCR and nes
202 Molecular Therapy: Nucleic Acids Vol. 13 December 2018the successful U7 snRNAs simultaneously deleted both exons 37
and 38. The results were confirmed by sequencing (Figure 3E).
Skipping efficacy was 15%–16% for U7.10 and U8.2 and 4% for
U9.2 (Figure 3D). We also compared our in vivo experiments to
in vitro attempts using the universal murine muscle cell line
C2C12. We could confirm that also in the in vitro model the U7.10
and U8.2 were the best performing antisense sequences and U9.2
was the least efficient one (12.9%) (Figure 3F).
U7 snRNA Antisense Sequences Skip Mouse Dysf Exons 37 and
38 in MMex38
We used the most potent rAAV2/9-U7 snRNAs (U7.10 and U8.2)
from MDX and C2C12 experiments to trigger exon skipping in vivo
in MMex38 mice, using the same transduction protocol (1.2  1011
vector genomes [VG] per tibialis anterior [TA]). MMex38 mice
were 8 weeks of age and did not show any signs of muscular dystrophy
yet. Analysis also was performed 4 weeks after the injection. U7.10
and U8.2 triggered simultaneous skipping of exons 37 and 38 (Figures
4A and 4B). Single exons were not skipped. The overall skipping
efficiency reached 6.6% (Figure 4A). On the protein level, an increase
in dysferlin expression to a level of about 20% of theWTwas observedivity in MDX Mice and C2C12 Cells
and intron 38–39 of mouse dysferlin pre-mRNA. (B) Primer localization. (C) Detection
ands represent a heteroduplex formed between the full and skipped PCR product.53
pped dysferlin. The presence of the junction between exons 36 and 39 was verified.
ted PCR in C2C12 cells. LD, low dose; HD, high dose.
www.moleculartherapy.orgfor two TAs injected with the U7.10 antisense sequence (Figure 4C).
In immunostaining of sample 3L, we were able to detect a very small
amount of additional membrane-bound dysferlin (Figure 4D).
DISCUSSION
We generated MMex38 mice, the first mouse model of dysferlinop-
athy with a Dysf missense mutation rather than the complete
knockout models described thus far.2,10–14 The mutation closely
resembles a clinically relevant mutation also present in a cohort of
patients.8 We succeeded to skip the mutation-containing exon by
U7 snRNA-mediated exclusion, and we demonstrate that dysferlin
after removal of exons 37 and 38 is functional.
Up to now, few muscular dystrophy mouse models exist carrying
disease-specific missense mutants. Many attempts failed to reproduce
a clinical phenotype in mice.37,38 A missense mutant of a gene encod-
ing for a sarcolemmal protein allows for gene editing, for interference
with protein folding and degradation, as well as for exploring over-
arching concepts of how membrane integrity could be maintained
in muscular dystrophy.
Exon-skipping strategies are one of the most promising approaches
for muscular dystrophies and could be particularly useful to eliminate
mutations. Exon skipping is generally induced by antisense oligonu-
cleotides. However, there are several reasons why U7 snRNAs might
be preferable. Once delivered to tissue, U7 snRNAs can be expressed
constantly without the need for a repeated administration as is the
case with the synthetic antisense oligonucleotides. Furthermore,
embedding the antisense sequences into the U7 snRNA with an
optimized Sm protein-binding site assures their accumulation in
the nucleus,39,40 and it increases the probability of modifying the
constitutive splicing process. The U7 snRNA can be packaged into
rAAV and lentiviruses for an efficient and tissue-specific delivery.
They also can be combined with a cell therapy strategy to produce
primary cells expressing splice-switching molecules for later tissue
transplantation.41 In addition, U7 snRNA can be further modified
with sites for binding splicing repressor proteins to create a bifunc-
tional snRNA with enhanced skipping activity.42 Indeed, the U7
RNA approach for exon skipping has been proven to be efficient
and successful in dystrophinopathy. Dystrophin expression in the
MDX mouse model,29 dystrophin-utrophin knockout mice,43 and
also in large animals44,45 remarkably improved following treatment
with the AAV-U7 snRNA. Based on these promising results, clinical
trials are presently being designed and prepared.
In vivo skipping efficacy of exons 37 and 38 in MMex38 mice reached
only 6.6% compared to 16% using the same U7 snRNA in the MDX
mice. There are several possibilities that could explain this discrep-
ancy. The lack of dysferlin at the sarcolemma in MMex38 mice could
have an impact on viral transduction efficiency into the fiber. Alter-
natively, the difference might have arisen from the fact that, in the
case of MMex38 mice, a healthy presymptomatic muscle was treated,
whereas in the MDX model the muscle was in constant cycles of
necrosis and regeneration. Viral uptake may be facilitated duringregeneration. It is a peculiarity of dysferlinopathies that patients
and mice are free of symptoms and myopathological alterations until
adulthood. We identified the first histological signs of a muscular
dystrophy in 12-week-old MMex38 mice, but exon-skipping
treatment was initiated at 8 weeks of age. There is a good rationale
to initiating treatment as early as possible and even performing a
screening for muscular dystrophies in newborns.46 However, apart
from ethical questions, our findings of inferior treatment efficacy in
a presymptomatic setting adds another aspect to this discussion.
It is estimated that only small amounts of dysferlin are required to
promote functionality and to prevent progressive muscle loss.12 It
is, therefore, possible that skipping efficacy of 6%–7% maximally as
shown here might be sufficient to interfere with the course of the
disease. On the mRNA level, U7.10 4L resulted in the best skipping
efficiency, and on the protein level the highest dysferlin expression
was seen in U7.10 3L and 3R. This discrepancy is attributed to both
muscle sampling from different parts of TA and uneven distribution
of AAV after an intramuscular injection. Only future experiments
designed to treat the entire animal rather than a single muscle will
be able to estimate the success of our approach. Optimization of
the exon-skipping tool would be also required. For instance, new
antisense sequences might trigger a stronger exon-skipping effect.
Use of bifunctional U7 snRNAs,42 which contain both antisense
sequence and a splice enhance sequence, could be another option
for improving the skipping efficiency.
MATERIALS AND METHODS
Animal Work
The MMex38 mice were kept at the Animal Facility of Max Delbrück
Center for Molecular Medicine, Berlin. All experiments performed
in Berlin were approved by the local governmental authority (Land-
esamt für Gesundheit und Soziales Berlin, Germany). Breeding and
characterization of the MMex38 mouse strain were performed under
the licenses G0065/13 and G0257/14, and exon-skipping experiments
were under the license G0145/16. The exon-skipping experiments
with MDX mice were performed in France at UFR des sciences de
la santé Simone Veil-Université de Versailles Saint-Quentin-en-
Yvelines under the license APAFIS6518-2016081715535828 v2
from the Ministère de lʼEnseignement supérieur de la Recherche et
de lʼInnovation.
MMex38 Mouse Model Generation
Three homological arms of genomic Dysf were derived by PCR from
embryonic stem cell (ESC) DNA of the 129 strain. The target T > C
mutation in Dysf exon 38 leading to Dysf p.Leu1360Pro (dysferlin
isoform 2, NCBI GenPept: NP_001071162.1) was introduced by
site-directed mutagenesis. The targeting vector consisted of a
4.8-kb-long 50-targeting arm, including genomic DNA spanning
from Dysf intron 36 to exon 38 (50 long homology arm), a 150-bp
50 short targeting arm containing genomic DNA from Dysf exon
and intron 38 (50 short homology arm), and a 30-targeting arm con-
taining 1.5 kb of genomic DNA from intron 38 (30 homology arm)
(Figure S1). The targeting vector included a LoxP site-flankedMolecular Therapy: Nucleic Acids Vol. 13 December 2018 203
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50 short and 30 homology arms, flanked by genomic sequence of Dysf
intron 38). Primers are listed in Table S2. The plasmid was confirmed
by sequencing.
After linearization, we performed electroporation, and the targeting
construct was inserted by homologous recombination into ESCs
(129ola). Cells were initially selected via their neomycin resistance.
We confirmed correct genomic insertion by PCR and sequencing.
We used correctly targeted ESCs to perform microinjection into
C57BL/6 blastocysts and generate knockin mice using standard tech-
niques (Transgenic Core Facility, Max Delbrück Center for Molecular
Medicine, Berlin). The MMex38 strain was generated by crossing
transgenic animals with a ubiquitous Cre deleter mouse strain. The
founder line was backcrossed on a C57BL/6N genetic background
5 times before mouse model characterization was performed
(B6;129P2-Dysftm1.1Mdcb). In all experiments WT littermates served
as controls. Mice were genotyped by PCR of ear-tag DNA using
AmpliTaq Gold 360 DNA Polymerase (Thermo Fisher Scientific,
Darmstadt, Germany), and primers are listed in Table S3 as well as
illustrated in Figure S1.
Histochemistry and Histopathology
Trichrome and Congo red staining were performed according to stan-
dard protocols. Images were collected using either the Leica DMI6000
(Leica Microsystems, Wetzlar, Germany) or the Zeiss LSM 700
confocal microscope (Carl Zeiss, Germany). Digital images were
processed using the LAS AF software (Leica) or the Zeiss LSM
ZEN software (Carl Zeiss, Jena, Germany). Quantification of
histopathology was performed counting the number of regenerating
fibers, necrotic fibers, and fibers with centralized nuclei per 100
fibers. Fiber diameter was determined using ImageJ software (Wayne
Rasband, NIH, Bethesda, MD, USA).
Membrane Repair Assay of Single Muscle Fibers and Dysferlin-
Null Primary Human Myotubes
Flexor digitorum brevis muscle was isolated and dissolved in mini-
mum essential medium (MEM), fetal calf serum (FCS, 10%), and
collagenase 1 for 3 hr at 37C. Under the microscope, connective
tissue and vessels were removed and muscle fibers were gently sepa-
rated. By pipetting, single muscle fibers were isolated from the fiber
bundle and fixated on laminin-coated atomic force microscopy
(AFM) basins with MEM, FCS (10%), and gentamycin ( = Complete
MEM) overnight. Fibers were washed with Tyrode solution (5 mM
KCl, 140 mMNaCl, 2 mMMgCl2, 2.5 mMCaCl2, and 10mMHEPES
[pH 7.2]).3 2.5 mM FM1-43 fluorescent dye was added to the
fibers. Laser wounding was performed by irradiation of an area of
5  5 mm at the fiber membrane using all four lasers of the
Zeiss LSM 700 laser microscope with a total power of 30 MW.
Myoblasts were differentiated in 3.5-cm glass-bottom dishes (ibidi,
Martinsried, Germany). The assay was performed in 1 mL Tyrode
solution supplemented with 2.5 mL 1 mM FM4-64 fluorophore
(Invitrogen, Darmstadt, Germany). Myotubes were wounded by
irradiating amembranous area of 2.5 2.5 mm for 60 s. In both exper-204 Molecular Therapy: Nucleic Acids Vol. 13 December 2018imental settings, a single image was taken before irradiation and
further pictures were recorded in time series every 20 s after wound-
ing to observe the changes in the fluorescence intensity over time.
Fluorescent intensities were measured using ImageJ software (Wayne
Rasband, NIH, Bethesda, MD, USA).
Western Blot
The muscle tissue was dissolved in 50 mM Tris, 150 mM NaCl, 0.5%
Triton X-100, 0.5% Na-Deoxycholate, 1 mM EDTA, 50 mM NaF,
1 mM Na3VO4, 1 mM PMSF, and 1 Complete (Roche, Mannheim,
Germany) for 30 min; centrifuged for 15 min (13,200 rpm); and the
supernatant was collected. Antibodies used for western blot were
mouse anti-dysferlin mab HAMLET (Novocastra, Wetzlar, Ger-
many), rabbit anti-dysferlin mab ROMEO (ab124684, Abcam), and
mouse a-tubulin mab T5168 (Sigma-Aldrich, St. Louis, MO, USA).
For the biotin-streptavidin detection system, a biotin-conjugated sec-
ondary antibody donkey anti-mouse (Dianova, Hamburg, Germany)
together with high-sensitivity streptavidin-horseradish peroxidase
(HRP) (Thermo Fisher Scientific, Rockford, IL, USA) was used.West-
ern blots were detected by chemiluminescence (Amersham ECL
Advance Western Blotting Detection Kit; GE Healthcare) or by the
ODYSSEY infrared imaging system (LI-COR Biosciences, Lincoln,
NE, USA).
Cell Culture and Differentiation into Myotubes
The human primary myoblasts and C2C12 cells were cultured in a
humidified incubator at 37C with 5% CO2 in in Skeletal Muscle
Cell Growth Medium (Provitro, Berlin, Germany) containing 15%
FCS, fetuin, human recombinant epidermal growth factor (hEGF),
human recombinant fibroblast growth factor (bFGF), insulin, dexa-
methasone, gentamicin, and amphothericin B and enriched with
1 glutamax (Life Technologies). For differentiation of human pri-
mary myoblasts or C2C12, cells were grown up to 70% confluency
and the medium was changed to Opti-MEM reduced serum medium
(Life Technologies) supplemented with 2% horse serum (Lonza,
Basel, Switzerland).
Immunostainings
Transversal muscle tissue cryosections of 6 mmwere fixed for 5 min in
acetone at 20C and blocked with 1% BSA in PBS for 45 min at
room temperature. Sections were incubated overnight at 4C with
the primary ROMEO anti-Dysferlin rabbit monoclonal antibody
(Abcam, Cambridge, UK, 1:100). Sections were incubated with the
secondary goat anti-rabbit Cy3-conjugated antibody (Dianova,
Hamburg, Germany, 1:500) for 45 min at room temperature. Nuclei
were stained with Hoechst. The sections were mounted with
AquaMount (Polysciences, Hirschberg, Germany). Cells were seeded
on glass-bottom plates (ibidi, Martinsried, Germany) and fixed with
3.7% formaldehyde for 10 min at room temperature. Cells were
permeabilized with 0.2% Triton X-100 in PBS for 5 min at room
temperature. Cells were blocked with 1% BSA in PBS for 1 hr at
room temperature and incubated overnight at 4C with two primary
antibodies: mouse monoclonal antibody anti-Desmin (Dako,
Jena, Germany; 1:100) and rabbit monoclonal antibody ROMEO
www.moleculartherapy.organti-Dysferlin (Abcam, 1:150). Cells were incubated for 1 hr at room
temperature with the following secondary antibodies (both diluted to
1:500): polyclonal Alexa 568 donkey anti-rabbit (Life Technologies)
and polyclonal Alexa 647 goat anti-mouse (Life Technologies). Nuclei
were stained with Hoechst.
Cloning of Dysferlin Constructs
The four versions of dysferlin protein (hDYSF_Full, hDYSF_D37,
hDYSF_D38, and hDYSF_D3738) connected to EGFP via P2A
peptide were made from the plasmids containing full-length human
dysferlin cDNA pUC57-Kan-DysfFull and truncated human dysfer-
lin cDNA pUC57-Kan-DysfDex37 and pUC57-Kan-DysfDex38,
obtained as a gift from the Jain Foundation. The pUC57-Kan-
DyfDex37&38 plasmid was constructed using whole-plasmid PCR
with Phusion Master Mix (Thermo Fisher Scientific) and P11cF,
P11aR primers (Table S4). For further clonining, the dysferlin
cDNA was amplified with c25F, c25R and c26F, c26R primers. The
P2A sequence was obtained from lentiCRISPR v2, which was a gift
from Feng Zhang (Addgene plasmid 52961).47 The dysferlin con-
structs were connected to EGFP and P2A via PCR reactions with
the cP23F, cP23R, cP24F, cP24R, and DYSF-Seq1R primers (Table
S4), and they were cloned into the pRRLSIN.cPPT.PGK-MCS.WPRE
plasmid used for the lentivirus production. The constructs were veri-
fied by sequencing.
Lentivirus Production
Third-generation,48 self-inactivating lentiviral vectors49 were pro-
duced in the L.G. laboratory at Université de Versailles Saint-
Quentin-en-Yvelines, France, using quadri-transfection of 293T cells.
Sequences encoding Gag, Pol, and Rev proteins were delivered on
pMDLg/pRRE and pRSV-Rev packaging plasmids, whereas the vesic-
ular stomatitis virus envelope glycoprotein (VSV-G) was delivered
on pMD2.G plasmid. The viral long terminal repeats (LTRs) with
dysferlin gene connected to EGFP and under the control of human
phosphoglycerate kinase-1 (PGK-1) promoter were delivered on the
pRRLSIN.cPPT.PGK-MCS.WPRE plasmid. At 3 days after transfec-
tion of 293T cells, the supernatant was collected and centrifuged at
3,500  g for 30 min and filtered via a 0.3-mm filter. The filtered
supernatant was further concentrated using tangential flow
filtration system from Specturm Labs. The concentrate was centri-
fuged for 2 hr at 20,000 rpm with Beckmann ultracentrifuge, and
the viral pallet was resuspended in PBS, aliquoted, and frozen at
80C. Viral titer was estimated by means of Lenti-X qRT-PCR
Titration Kit (Clontech Laboratories, Saint-Germain-en-Laye,
France) and titration by infection using flow cytometry.
Lentiviral Transduction of Dysferlin-Null Myoblasts with
Dysferlin Constructs and FACS
Dysferlin-null human primary myoblasts (exon 44: c.4872delG) were
transduced with lentivirus carrying full and truncated dysferlin
constructs at an MOI of 2. The cells were seeded at the density of
25,000 cells/well. The next day the cells were washed with PBS and
medium was changed. An appropriate amount of virus was added.
The cells were inoculated with the virus for 24 hr and afterwardcultured to obtain enough cells for fluorescence-activated cell sorting
(FACS). The cells were stained with the primary mouse monoclonal
antibody anti-CD56-NCAM (Miltenyi Biotec, Bergisch Gladbach,
Germany) 1:200 in combination with the secondary Alexa 647 goat
anti-mouse antibody (Invitrogen) 1:500. The cells were sorted using
BD FACSaria F cell sorter to enrich for the myoblast population
expressing high levels of EGFP signal.
Cloning of Antisense Sequences into U7 snRNA Backbone
The U7 snRNA backbone was modified using cP21_F, cP21_R and
XbaI_F, NheI_R primers (Table S4) in order to introduce the BbsI
and EcoRI restriction sites for later cloning of the antisense sequences.
The U7 antisense sequences were ordered at Eurogentech, Seraing,
Belgium, as two complementary single-stranded oligonucleotides
with BbsI overhangs at the 50 and 30 ends. The pSMD2-U7-BbsI
plasmid was digested with BbsI restriction enzyme (New England
Biolabs), and the annealed antisense oligonucleotides were cloned
into the vector. The correctness of U7 antisense sequence was verified
by sequencing.
rAAV Production
The rAAV2/9 for the test in MDX mice was produced in the L.G.
laboratory at Université de Versailles Saint-Quentin-en-Yvelines,
France. The production was done using the tri-transfection method50
combined with the downstream detergent treatment, according to
the protocol of Dias Florencino and colleagues.51 For tri-transfection,
a plasmid pAAV2/9 encoding replication and capsid proteins, a
helper plasmid pXX6, and a transgene encoding plasmid pSMD2
were used. The rAAV2/9 for the C2C12 cell experiment was produced
in the L.G. laboratory at Université de Versailles Saint-Quentin-en-
Yvelines, France, using the baculovirus expression system in SF9
insect cells, according to the Buclez et al.52 protocol. The rAAV2/9
titers for all productions were estimated by qPCR. The rAAV2/9
for the in vivo injections into MMex38 was produced using the
tri-transfection method and titrated at Charite Viral Core Facility
in Berlin, Germany.
Transduction of AAV-U7 snRNAs into C2C12 Cells
The C2C12 cells were seeded at the density of 500,000 cells/well in a
6-well plate. The next day the cells were washed with PBS and me-
dium was changed. 5  1011 VG for a low dose and 5  1012 VG
for a high dose of AAV-U7 snRNAs were added, and the cells were
inoculated with the virus for 24 hr. Next the medium was changed
to a differentiation medium (DMEM, 2% horse serum, 1% PenStrep),
and the cells were differentiated for 5 days.
Intramuscular Injections of AAV-U7 snRNAs into the TA Muscle
of Mice
The U7 snRNAs packaged in rAAV2/9 and dissolved in PBS were
delivered as an intramuscular injection into the TA muscle at
the amount of 1.2  1011 VG/TA for the MMex38 mice and
1.32  1011 VG/TA for the MDX mice. For this purpose, 2-month-
old MMex38 mice and 2.5- or 3-month-old MDXmice were anesthe-
tized by inhalation of 2% isoflurane, hind limbs were shaved, andMolecular Therapy: Nucleic Acids Vol. 13 December 2018 205
Molecular Therapy: Nucleic Acidsinjections were made with an insulin syringe. The mice were sacri-
ficed by cervical dislocation 4 weeks after the injection, and the mus-
cle was harvested for the analysis.
RNA Isolation and RT-PCR Analysis
Total RNA was isolated from cells or mouse TA muscle using TRIzol
Reagent (Life Technologies), according to the manufacturer’s proto-
col. For the RNA isolation, the muscle samples were homogenized in
Precellys24 (Bertin Instruments, Montigny-le-Bretonneux, France) at
5,000 rpm for 45 s and at 6,800 rpm for 15 s. RNA was resuspended in
RNase-free water, incubated in heat block at 55C for 15 min, and
finally stored at 80C. Between 0.5 and 1 mg total RNA was used
in a reverse transcription reaction. For the detection of exon skipping,
the reverse transcription and PCR reactions were done using Access-
Quick RT-PCR System (Promega, Mannheim, Germany) using a pair
of external primers, mP3F (50-TCTTTGACTATGGGAACCGCT-30)
and mP3R (50-CTGTGGGGATGGACTCTCTG-30). 2 mL PCR prod-
uct and a pair of internal primers, mP2F (50-AAGCCAGAAGACAG
TGGTGG-30) and mP2R (50-GAGTATGGGTCGCACAGGAA-30),
were taken for the nested PCR reaction using GoTaq Master Mix
(Promega). The nested PCR product was analyzed for the skipped
exons on an agarose gel. The level of exon skipping was estimated
by densitometry method using ImageJ (Wayne Rasband, NIH,
Bethesda, MD, USA) quantification.
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